ArticleRespiratory research2026
Increased potential for atherogenic changes in asthma: evidence from transcriptomic studies of arterial endothelial cells.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAsthma is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), yet the mechanistic pathways underlying this relationship remain poorly defined. Clinical ASCVD is initiated by arterial injury, with endothelial dysfunction representing the earliest detectable stage. We aimed to characterize the differential transcriptomic response of naïve arterial endothelial cells (AECs) exposed to serum from individuals with and without asthma, using a novel stem cell-derived AEC model.
methodsPluripotent-derived naïve AECs were incubated with serum from individuals with asthma or healthy controls for 6 and 24 h. RNA sequencing was performed on AEC lysates, genes were compared between asthma and healthy control serum treatments, and differentially expressed genes were identified. Functional enrichment and pathway analyses were conducted using DAVID, ShinyGO, and STRING. Statistical significance was determined using false discovery rate (FDR)-adjusted p values to account for multiple comparisons.
resultsAfter 6 h of exposure to asthma serum, genes associated with biological processes of endothelial cell proliferation, angiogenesis, migration, and focal adhesion assembly (FDR-adjusted p = 0.04) were significantly enriched among upregulated genes (compared to among all genes, p = 0.0002, 0.004, and 0.04, respectively). Enriched pathways included adhesion junction, mitogen-activated protein kinase, neurotrophin, hypoxia-inducible factor-1, and Wnt signaling (p = 0.00001, 0.00004, 0.002, 0.002, 0.00001, and 0.01). At both 6 and 24 h, pathways related to lipid and atherosclerosis (p = 0.02), epidermal growth factor (EGF) receptor (p = 0.03 and 0.02 at 6 and 24 h), advanced glycation end products (AGE)-receptor for AGEs (RAGE) (p = 0.03 and 0.001), and Ras (p = 0.04 and 0.03) and Rap1 (p = 0.04 and 0.046) signaling were upregulated. Fibronectin (FN1), a central hub in the STRING network, was the highest expressed among upregulated genes at 6 h. Other central genes included EGF, vascular endothelial growth factor A and fibroblast growth factor receptor 1.
conclusionsSerum from individuals with asthma, compared to serum from healthy donors, induced gene expression alterations in a novel model of naïve AECs. These transcriptional changes are consistent with early cellular injury, including pathways of lipid-atherosclerosis, endothelial cell activation, adhesion, and AGE-RAGE signaling. These findings indicate that circulating factors in asthma activate arterial endothelial cells to promote early vascular injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.